The global prostate cancer therapeutics market is experiencing significant growth, driven by advancements in treatment options, increasing prevalence of the disease, and rising awareness among patients and healthcare providers. This article delves into the current landscape, key players, recent developments, market drivers and restraints, segmentation, regional insights, and future scope of the market.
The prostate cancer therapeutics market was valued at USD 19.81 billion in 2024. It is expected to grow from USD 25.12 billion in 2025 to USD 101.98 billion by 2032, demonstrating a strong compound annual growth rate (CAGR) of 22.2% over the forecast period. North America held the largest market share in 2024, accounting for 50.98%.
In December 2024, AbbVie Inc. initiated a Phase 1 clinical trial for ABBV-969, targeting the treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). This development underscores the company's commitment to expanding its oncology portfolio and addressing unmet needs in prostate cancer treatment.
Drivers: